ArticleOncotarget2017
Analysis of
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.Breast cancer research : BCR · 2025Trial
- Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence.Cancer research communications · 2026Article
- Review
- Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment.Discover oncology · 2025Review
- The Combined Assessment of CTC andInternational journal of molecular sciences · 2025Article
- Subtype-specific prognostic implications of plasma-detectedFrontiers in oncology · 2025Article
- Serial analysis ofFrontiers in oncology · 2025Article
- Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.ESMO open · 2024Article
- Review
- Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature.World journal of oncology · 2023Article
- Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.Molecular biology reports · 2022Review
- Review
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.Genome medicine · 2021Article
- The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.Oncology letters · 2021Article
- Review
- Preexisting Somatic Mutations of Estrogen Receptor Alpha (JNCI cancer spectrum · 2021Article
- Article
- The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe measurement of
methodsThe subjects of this retrospective study were a total of 185 plasma samples from 86 estrogen receptor-positive BC patients, of which 151 plasma samples were from 69 MBC patients and 34 plasma samples were from 17 primary BC (PBC) patients. We developed multiplex droplet digital PCR assays to verify the clinical significance of
resultscfDNA
conclusionsWe have demonstrated the clinical significance of on-treatment
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.